HIGHLIGHTS
- who: Fabio Giglio et al. from the University of Udine, Italy have published the research work: Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia, in the Journal: (JOURNAL)
- what: The analysis shows a significant peak occurring within the first week after treatment. This activity can induce a reversible function-off state in CAR-T_cells that can be exploited to mitigate CRS and to improve CAR-T_cell fitness by preventing exhaustion and promoting the acquisition of a memory-like phenotype . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.